Is Bristol Myers Stock a Good Investment?
Bristol Myers Investment Advice | BMY |
- Examine Bristol Myers' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bristol Myers' leadership team and their track record. Good management can help Bristol Myers navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Bristol Myers' business and its evolving consumer preferences.
- Compare Bristol Myers' performance and market position to its competitors. Analyze how Bristol Myers is positioned in terms of product offerings, innovation, and market share.
- Check if Bristol Myers pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bristol Myers' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bristol Myers Squibb stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bristol Myers Squibb is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Bristol Myers Stock
Researching Bristol Myers' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 78.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 2.03. Bristol Myers Squibb recorded a loss per share of 3.56. The entity last dividend was issued on the 4th of October 2024. The firm had 1000000:95 split on the 7th of August 2001.
To determine if Bristol Myers is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bristol Myers' research are outlined below:
| Bristol Myers Squibb has a strong financial position based on the latest SEC filings | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| On 1st of November 2024 Bristol Myers paid $ 0.6 per share dividend to its current shareholders | |
| Latest headline from businesswire.com: From The Dilenschneider Group Former MetroHealth CEO Dr. Akram Boutros Refiles Civil Damages Case |
Bristol Myers Quarterly Accounts Payable |
|
Bristol Myers uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bristol Myers Squibb. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bristol Myers' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Bristol Myers' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bristol Myers' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2006-10-26 | 2006-09-30 | 0.2 | 0.22 | 0.02 | 10 | ||
2007-01-25 | 2006-12-31 | 0.16 | 0.19 | 0.03 | 18 | ||
2006-01-25 | 2005-12-31 | 0.28 | 0.31 | 0.03 | 10 | ||
2002-07-23 | 2002-06-30 | 0.26 | 0.23 | -0.03 | 11 | ||
2015-10-27 | 2015-09-30 | 0.35 | 0.39 | 0.04 | 11 | ||
2003-03-10 | 2002-12-31 | 0.27 | 0.31 | 0.04 | 14 | ||
2015-01-27 | 2014-12-31 | 0.41 | 0.46 | 0.05 | 12 | ||
2009-01-27 | 2008-12-31 | 0.41 | 0.46 | 0.05 | 12 |
Know Bristol Myers' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bristol Myers is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bristol Myers Squibb backward and forwards among themselves. Bristol Myers' institutional investor refers to the entity that pools money to purchase Bristol Myers' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 21.2 M | Legal & General Group Plc | 2024-06-30 | 20.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 19.1 M | Bank Of America Corp | 2024-06-30 | 18.2 M | Ameriprise Financial Inc | 2024-06-30 | 17.7 M | Bank Of New York Mellon Corp | 2024-06-30 | 16.2 M | Goldman Sachs Group Inc | 2024-06-30 | 15.7 M | Dodge & Cox | 2024-09-30 | 15.6 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 15.3 M | Vanguard Group Inc | 2024-09-30 | 188.6 M | Blackrock Inc | 2024-06-30 | 158.7 M |
Bristol Myers' market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 118.1 B.Market Cap |
|
Bristol Myers' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.17 | 0.15 | |
| Return On Capital Employed | 0.23 | 0.29 | |
| Return On Assets | 0.08 | 0.14 | |
| Return On Equity | 0.27 | 0.30 |
Determining Bristol Myers' profitability involves analyzing its financial statements and using various financial metrics to determine if Bristol Myers is a good buy. For example, gross profit margin measures Bristol Myers' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bristol Myers' profitability and make more informed investment decisions.
Bristol Myers' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Bristol Myers' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myers Squibb. Check Bristol Myers' Beneish M Score to see the likelihood of Bristol Myers' management manipulating its earnings.
Evaluate Bristol Myers' management efficiency
Bristol Myers Squibb has Return on Asset of 0.0607 % which means that on every $100 spent on assets, it made $0.0607 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3133) %, meaning that it generated no profit with money invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Bristol Myers' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop 0.15 in 2024. At this time, Bristol Myers' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 66.6 B in 2024, whereas Other Assets are likely to drop slightly above 3.3 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.25 | 14.96 | |
| Tangible Book Value Per Share | (9.07) | (8.61) | |
| Enterprise Value Over EBITDA | 7.01 | 12.19 | |
| Price Book Value Ratio | 3.61 | 6.92 | |
| Enterprise Value Multiple | 7.01 | 12.19 | |
| Price Fair Value | 3.61 | 6.92 | |
| Enterprise Value | 107.1 B | 112.4 B |
Bristol Myers Squibb has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Dividend Yield 0.0412 | Forward Dividend Yield 0.0412 | Forward Dividend Rate 2.4 | Beta 0.441 |
Basic technical analysis of Bristol Stock
As of the 21st of November, Bristol Myers shows the Downside Deviation of 1.48, mean deviation of 1.34, and Risk Adjusted Performance of 0.1157. Bristol Myers Squibb technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Bristol Myers' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bristol Myers insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bristol Myers' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bristol Myers insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Peter Arduini over three months ago Acquisition by Peter Arduini of 825 shares of Bristol Myers subject to Rule 16b-3 | ||
Hoch Lynelle over six months ago Disposition of 1050 shares by Hoch Lynelle of Bristol Myers subject to Rule 16b-3 | ||
Phyllis Yale over a year ago Acquisition by Phyllis Yale of 581 shares of Bristol Myers subject to Rule 16b-3 |
Bristol Myers' Outstanding Corporate Bonds
Bristol Myers issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bristol Myers Squibb uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bristol bonds can be classified according to their maturity, which is the date when Bristol Myers Squibb has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BRISTOL MYERS SQUIBB Corp BondUS110122AB49 | View | |
| BRISTOL MYERS SQUIBB Corp BondUS110122BB30 | View | |
| BRISTOL MYERS SQUIBB Corp BondUS110122AX68 | View | |
| US110122AP35 Corp BondUS110122AP35 | View | |
| BRISTOL MYERS SQUIBB Corp BondUS110122AU20 | View | |
| BMY 37 15 MAR 52 Corp BondUS110122DW58 | View | |
| BMY 39 15 MAR 62 Corp BondUS110122DX32 | View | |
| BRISTOL MYERS SQUIBB CO Corp BondUS110122DQ80 | View |
Understand Bristol Myers' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bristol Myers' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1157 | |||
| Market Risk Adjusted Performance | 2.35 | |||
| Mean Deviation | 1.34 | |||
| Semi Deviation | 1.25 | |||
| Downside Deviation | 1.48 | |||
| Coefficient Of Variation | 688.15 | |||
| Standard Deviation | 1.99 | |||
| Variance | 3.96 | |||
| Information Ratio | 0.0973 | |||
| Jensen Alpha | 0.2689 | |||
| Total Risk Alpha | 0.0535 | |||
| Sortino Ratio | 0.1305 | |||
| Treynor Ratio | 2.34 | |||
| Maximum Drawdown | 14.39 | |||
| Value At Risk | (2.07) | |||
| Potential Upside | 2.23 | |||
| Downside Variance | 2.2 | |||
| Semi Variance | 1.57 | |||
| Expected Short fall | (1.50) | |||
| Skewness | 2.2 | |||
| Kurtosis | 10.33 |
| Risk Adjusted Performance | 0.1157 | |||
| Market Risk Adjusted Performance | 2.35 | |||
| Mean Deviation | 1.34 | |||
| Semi Deviation | 1.25 | |||
| Downside Deviation | 1.48 | |||
| Coefficient Of Variation | 688.15 | |||
| Standard Deviation | 1.99 | |||
| Variance | 3.96 | |||
| Information Ratio | 0.0973 | |||
| Jensen Alpha | 0.2689 | |||
| Total Risk Alpha | 0.0535 | |||
| Sortino Ratio | 0.1305 | |||
| Treynor Ratio | 2.34 | |||
| Maximum Drawdown | 14.39 | |||
| Value At Risk | (2.07) | |||
| Potential Upside | 2.23 | |||
| Downside Variance | 2.2 | |||
| Semi Variance | 1.57 | |||
| Expected Short fall | (1.50) | |||
| Skewness | 2.2 | |||
| Kurtosis | 10.33 |
Consider Bristol Myers' intraday indicators
Bristol Myers intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bristol Myers stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bristol Myers Corporate Filings
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 31st of July 2024 Other Reports | ViewVerify |
Bristol Stock media impact
Far too much social signal, news, headlines, and media speculation about Bristol Myers that are available to investors today. That information is available publicly through Bristol media outlets and privately through word of mouth or via Bristol internal channels. However, regardless of the origin, that massive amount of Bristol data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bristol Myers news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bristol Myers relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bristol Myers' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bristol Myers alpha.
Bristol Myers Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bristol Myers can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bristol Myers Squibb Historical Investor Sentiment
Investor biases related to Bristol Myers' public news can be used to forecast risks associated with an investment in Bristol. The trend in average sentiment can be used to explain how an investor holding Bristol can time the market purely based on public headlines and social activities around Bristol Myers Squibb. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bristol Myers' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bristol Myers and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Bristol Myers news discussions. The higher the estimate score, the more favorable the investor's outlook on Bristol Myers.
Bristol Myers Corporate Directors
| Karen Vousden | Independent Director | Profile | |
| Michael Bonney | Independent Director | Profile | |
| Robert Bertolini | Independent Director | Profile | |
| Gerald Storch | Independent Director | Profile |
Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.